# Kesuting Syrup in the Treatment of Corona Virus Disease 2019 (COVID-19)

> **NCT05366231** · PHASE4 · COMPLETED · sponsor: **Guizhou Bailing Group Pharmaceutical Co Ltd** · enrollment: 200 (actual)

## Conditions studied

- COVID-19 Pneumonia
- Cough

## Interventions

- **DRUG:** Kesuting syrup
- **DRUG:** LianHuaQingWen Granules

## Key facts

- **NCT ID:** NCT05366231
- **Lead sponsor:** Guizhou Bailing Group Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-08
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366231, "Kesuting Syrup in the Treatment of Corona Virus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05366231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*